Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps  Latest publication
Sargassum horneri polysaccharide extract
Potential treatment - pre-clinical evidence Natural product Antiviral Apr/15/2021
Tixagevimab
Emergency use authorization Experimental Antiviral Jun/18/2022
2-Hydroxy-4-(2-(tosyloxy)acetamido)benzoic acid
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/28/2021
8-{3-hydroxy-4-[(7-hydroxynaphthalen-2-yl)oxy]phenoxy}-1,4-benzodioxin-5-ol
Potential treatment - theoretical effect Experimental Antiviral Apr/25/2021
Litronesib
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
Phycoerythrobilin
Potential treatment - theoretical effect Natural product Antiviral Mar/20/2021
CoV2-09
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/20/2021
S2X324
Potential treatment - pre-clinical evidence Experimental Antiviral Dec/23/2021
Pyridone 6
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/28/2021
Daclatasvir
Potential treatment - clinical evidence Used to treat other disease Antiviral Dec/18/2020
Flumatinib
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
Phycocyanobilin
Potential treatment - theoretical effect Natural product Antiviral Mar/20/2021
CoV2-26
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/20/2021
Lactoferrin
Potential treatment - pre-clinical evidence Natural product Antiviral Jan/23/2021
(5-Chloropyridin-3-yl) 1H-indole-4-carboxylate
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/28/2021
NK cells
Potential treatment - theoretical effect Used to treat other disease Antiviral Dec/23/2021
Velpatasvir
Potential treatment - theoretical effect Used to treat other disease Antiviral Mar/26/2021
Kasugamycin
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
GC376
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/28/2021
S-[2-[[(2R,3S,4R,5R)-3,4-Dihydroxy-5-(2-oxo-7H-pyrrolo[2,3-d]pyrimidin-3-yl)oxolan-2-yl]methoxy-[2-(2,2-dimethylpropanoylsulfanyl)ethoxy]phosphoryl]oxyethyl] 2,2-dimethylpropanethioate
Potential treatment - theoretical effect Experimental Antiviral Feb/01/2021